Missed a GLP-1 Dose? Restarting After a Gap Is a Different Question

Missing one GLP-1 dose does not create the same problem as being off treatment for several weeks. For one late dose, check the instructions for your exact medicine and formulation. After a longer gap, contact the prescriber before restarting, particularly if you previously used a higher dose or stopped because of side effects.

There is no reliable “missed shot” rule that covers semaglutide, tirzepatide, daily tablets and every compounded preparation. Brand names that contain the same active ingredient can still have different schedules and instructions.

Start with what actually happened

Before contacting the clinic or pharmacy, record the last dose taken, the usual schedule and how many doses have been missed. Include the reason: a delayed refill, illness, a procedure, intolerable nausea or a deliberate pause. The reason matters as much as the interval.

Check the package rather than relying on the name saved in an old portal message. If the pharmacy changed the formulation or concentration, include that information too. An old syringe instruction is not a dose-conversion guide for a new vial.

The prescribing team should also know if you started another weight medicine during the gap. Do not assume it is safe to overlap prescriptions while waiting for a response. Give the clinician the complete current medicine list.

What the branded instructions say

The table below summarizes selected U.S. label directions. It is not a personal dosing schedule or a substitute for the instructions accompanying your prescription.

Do not use the Zepbound window for a Wegovy prescription, or an injection rule for a tablet. If the exact timing is unclear, ask the pharmacist rather than guessing whether two doses would be too close together.

Why a previous dose may need reassessment

Both Wegovy and Zepbound use gradual escalation schedules to reduce gastrointestinal side effects¹². Having tolerated a dose before a break does not establish that it is the appropriate dose to resume now. The prescriber needs to account for the interval, prior response and current health.

This is especially important when the pause followed repeated vomiting, dehydration, significant abdominal pain or difficulty eating. A restart plan should address why treatment stopped, rather than simply issue another refill. Our side-effects guide helps organize those symptoms for the conversation.

If the medicine was held for surgery or endoscopy, ask the procedure and prescribing teams to coordinate. The anesthesia planning guide covers why food intake, recovery and the procedure instructions can matter alongside the number of days missed.

Compounded medication needs a pharmacy-specific answer

A compounded preparation is not an FDA-approved substitute with the brand's instructions automatically attached. Its concentration, added ingredients, supplied syringe and beyond-use date can differ. Request written directions from the prescriber and dispensing pharmacy for the actual product.

FDA has received reports of dosing errors with compounded injectable semaglutide, including confusion between milligrams, milliliters and syringe units³. That makes a formulation change during a restart particularly important to flag. Do not convert an internet dose chart into syringe units yourself.

Check that any remaining medication is still within its labeled use period and has been stored correctly. Having liquid left in a vial does not establish that it is suitable for the next injection. Our travel and storage guide explains why temperature exposure and the exact device matter.

Separate a late shipment from a clinical decision

If a delivery delay created the gap, ask who can arrange the replacement and who will prescribe the restart. A customer-service representative can resolve shipping without being the person qualified to choose the dose.

Keep a record of the promised delivery date, actual missed doses and the clinician's response. Before buying a longer plan, ask how the service handles an interruption caused by its own fulfillment problem. A discounted subscription is less useful if it leaves you unable to reach the prescriber when a restart question arises.

When comparing programs, look at continuity and cancellation alongside price. Our provider-selection guide includes questions about monitoring and follow-up. The month-to-month shortlist compares a narrower issue: the ongoing published bill, not the quality of restart care.

Pregnancy, breastfeeding and new medicines change the question

Tell the clinician if you may be pregnant, are planning pregnancy, have given birth or are breastfeeding. A pause across one of those changes is not a routine refill problem. The pregnancy guide and breastfeeding evidence guide explain why formulation and timing need individual review.

Likewise, report new prescriptions, hospitalization or a change in diabetes treatment. A plan written before the gap may no longer describe your circumstances. If the original clinician is unavailable, give the new clinician the prior dose history rather than just asking for the same strength.

Questions that should have clear answers

• Which medicine and formulation am I restarting?
• What dose and schedule has the prescriber chosen, and why?
• Do I need a new prescription or a different device?
• What should happen if nausea or poor intake returns?
• Who reviews the response before another increase?
• If this pause was related to a procedure, have both teams agreed on timing?

Get the instructions in writing and make sure the pharmacy label matches them. If a portal message and package directions conflict, resolve the difference before taking the dose.

A gap does not decide the long-term plan

An interruption can be a useful point to review goals, tolerability, access and cost. It does not automatically mean treatment has failed or that a higher dose is needed. Nor does it prove that an ongoing prescription is still appropriate.

If you are considering stopping for longer, discuss maintenance, nutrition and follow-up rather than repeatedly stopping and restarting without a plan. Our guide to stopping GLP-1 treatment addresses that broader decision. The immediate goal after a gap is a clear, product-specific clinical plan you can follow safely.